Pro-inflammatory signaling by IL-10 and IL-22: Bad habit stirred up by interferons?

Frontiers in Immunology

Volumn 4, Issue FRB, 2013, Pages

  Mühl, Heiko ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Inflammation; Interleukin 10; Interleukin 22; Signal transducer and activator of transcription; Type I interferons

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 22; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; RECOMBINANT INTERLEUKIN 10; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CROHN DISEASE; DRUG EFFICACY; ENDOTOXEMIA; ENTERITIS; HEPATITIS; HUMAN; INFLAMMATION; INFLUENZA A; LIVER PROTECTION; MACROPHAGE; MONOCYTE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN EXPRESSION; PSORIASIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURAL HOMOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TISSUE INJURY;

EID: 84878321565     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00018     Document Type: Article

References (162)

1. Antoniv, T. T., and Ivashkiv, L. B. (2006). Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 54, 2711-2721.
2. Aujla, S. J., Chan, Y. R., Zheng, M., Fei, M., Askew, D. J., Pociask, D. A., et al. (2008). IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14, 275-281.
3. Aujla, S. J., and Kolls, J. K. (2009). IL-22: a critical mediator in mucosal host defense. J. Mol. Med. 87, 451-454.
4. Axtell, R. C., de Jong, B. A., Boniface, K., van der Voort, L. F., Bhat, R., De Sarno, P., et al. (2010). T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412.
5. Axtell, R. C., Raman, C., and Steinman, L. (2012). Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin. Rev. Allergy Immunol. (in press).
6. Bachmann, M., Horn, K., Rudloff, I., Goren, I., Holdener, M., Christen, U., et al. (2010). Early production of IL-22 but not IL-17 by peripheral blood mononuclear cells exposed to live Borrelia burgdorferi: the role of monocytes and interleukin-1. PLoS Pathog. 6:e1001144. doi:10.1371/journal.ppat.1001144
7. Bachmann, M., Ulziibat, S., Härdle, L., Pfeilschifter, J., and Mühl, H. (2012). IFNα converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets. Biochem. Pharmacol. doi:10.1016/j.bcp.2012.11.004
8. Beebe, A. M., Cua, D. J., and de Waal Malefyt, R. (2002). The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev. 13, 403-412.
9. Berg, R. E., Crossley, E., Murray, S., and Forman, J. (2003). Memory CD8+ T cells provide innate immune protection against Listeria monocytogenes in the absence of cognate antigen. J. Exp. Med. 198, 1583-1593.
10. Bhattacharyya, S., Sen, P., Wallet, M., Long, B., Baldwin, A. S. Jr., and Tisch, R. (2004). Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood 104, 1100-1109.
11. Blaschitz, C., and Raffatellu, M. (2010). Th17 cytokines and the gut mucosal barrier. J. Clin. Immunol. 30, 196-203.
12. Boniface, K., Bernard, F. X., Garcia, M., Gurney, A. L., Lecron, J. C., and Morel, F. (2005). IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174, 3695-3702.
13. Boniface, K., Guignouard, E., Pedretti, N., Garcia, M., Delwail, A., Bernard, F. X., et al. (2007). A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin. Exp. Immunol. 150, 407-415.
14. Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S. T., Otte, J. M., et al. (2006). IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G827-G838.
15. Brennan, F. M. (1999). Interleukin 10 and arthritis. Rheumatology 38, 293-297.
16. Buruiana, F. E., Solá, I., and Alonso-Coello, P. (2010). Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2010, CD005109.
17. Cai, G., Kastelein, R. A., and Hunter, C. A. (1999). IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur. J. Immunol. 29, 2658-2665.
18. Chestovich, P. J., Uchida, Y., Chang, W., Ajalat, M., Lassman, C., Sabat, R., et al. (2012). Interleukin-22: implications for liver ischemia-reperfusion injury. Transplantation 93, 485-492.
19. Chevaliez, S., and Pawlotsky, J. M. (2007). Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 59, 1222-1241.
20. Colonna, M. (2009). Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31, 15-23.
21. Cooper, P. J., Fekade, D., Remick, D. G., Grint, P., Wherry, J., and Griffin, G. E. (2000). Recombinant human interleukin-10 fails to alter proinflammatory cytokine production or physiologic changes associated with the Jarisch-Herxheimer reaction. J. Infect. Dis. 181, 203-209.
22. Corinti, S., Albanesi, C., la Sala, A., Pastore, S., and Girolomoni, G. (2001). Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166, 4312-4318.
23. Cush, J. J., Splawski, J. B., Thomas, R., McFarlin, J. E., Schulze-Koops, H., Davis, L. S., et al. (1995). Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 38, 96-104.
24. Danese, S., Angelucci, E., Malesci, A., and Caprilli, R. (2008). Biological agents for ulcerative colitis: hypes and hopes. Med. Res. Rev. 28, 201-218.
25. de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., and de Vries, J. E. (1991). Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209-1220.
26. de Weerd, N. A., Samarajiwa, S. A., and Hertzog, P. J. (2007). Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282, 20053-20057.
27. Döcke, W. D., Asadullah, K., Belbe, G., Ebeling, M., Höflich, C., Friedrich, M., et al. (2009). Comprehensive biomarker monitoring in cytokine therapy: heterogeneous, time-dependent, and persisting immune effects of interleukin-10 application in psoriasis. J. Leukoc. Biol. 85, 582-593.
28. Downs, A. M., and Dunnill, M. G. (2000). Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin. Exp. Dermatol. 25, 351-352.
29. Duchmann, R., Schmitt, E., Knolle, P., Meyerzum Büschenfelde, K. H., and Neurath, M. (1996). Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 26, 934-938.
30. Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., and Sallusto, F. (2009). Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat. Immunol. 10, 857-863.
31. Dumoutier, L., de Heusch, M., Orabona, C., Satoh-Takayama, N., Eberl, G., Sirard, J. C., et al. (2011). IL-22 is produced by γC-independent CD25+ CCR6+ innate murine spleen cells upon inflammatory stimuli and contributes to LPS-induced lethality. Eur. J. Immunol. 41, 1075-1085.
32. Dumoutier, L., Van Roost, E., Ameye, G., Michaux, L., and Renauld, J. C. (2000). IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun. 1, 488-494.
33. Eddens, T., and Kolls, J. K. (2012). Host defenses against bacterial lower respiratory tract infection. Curr. Opin. Immunol. 24, 424-430.
34. Farkas, A., and Kemény, L. (2011). Interferon-α in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. Br. J. Dermatol. 165, 247-254.
35. Feng, D., Kong, X., Weng, H., Park, O., Wang, H., Dooley, S., et al. (2012). Interleukin-22 promotes proliferation of liver stem/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology 143, 188-198.
36. Fiorentino, D. F., Bond, M. W., and Mosmann, T. R. (1989). Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170, 2081-2095.
37. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., and O'Garra, A. (1991). IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815-3822.
38. Friedrich, M., Döcke, W. D., Klein, A., Philipp, S., Volk, H. D., Sterry, W., et al. (2002). Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J. Invest. Dermatol. 118, 672-677.
39. Fujihara, M., Ito, N., Pace, J. L., Watanabe, Y., Russell, S. W., and Suzuki, T. (1994). Role of endogenous interferon-beta in lipopolysaccharide-triggered activation of the inducible nitric-oxide synthase gene in a mouse macrophage cell line, J774. J. Biol. Chem. 269, 12773-12778.
40. Geboes, L., Dumoutier, L., Kelchtermans, H., Schurgers, E., Mitera, T., Renauld, J. C., et al. (2009). Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 60, 390-395.
41. Glocker, E. O., Kotlarz, D., Klein, C., Shah, N., and Grimbacher, B. (2011). IL-10 and IL-10 receptor defects in humans. Ann. N. Y. Acad. Sci. 1246, 102-107.
42. González-Navajas, J. M., Lee, J., David, M., and Raz, E. (2012). Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12, 125-135.
43. Gough, D. J., Messina, N. L., Clarke, C. J., Johnstone, R. W., and Levy, D. E. (2012). Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36, 166-174.
44. Gough, D. J., Messina, N. L., Hii, L., Gould, J. A., Sabapathy, K., Robertson, A. P., et al. (2010). Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol. 8:e1000361. doi:10.1371/journal.pbio.1000361
45. Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., et al. (2011). Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213-223.
46. Guo, B., Chang, E. Y., and Cheng, G. (2008). The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118, 1680-1690.
47. Hansen, M. L., Woetmann, A., Krejsgaard, T., Kopp, K. L., Søkilde, R., Litman, T., et al. (2011). IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity. Mol. Immunol. 48, 2087-2093.
48. Herrero, C., Hu, X., Li, W. P., Samuels, S., Sharif, M. N., Kotenko, S., et al. (2003). Reprogramming of IL-10 activity and signaling by IFN-gamma. J. Immunol. 171, 5034-5041.
49. Hida, S., Ogasawara, K., Sato, K., Abe, M., Takayanagi, H., Yokochi, T., et al. (2000). CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13, 643-655.
50. Hoegl, S., Bachmann, M., Scheiermann, P., Goren, I., Hofstetter, C., Pfeilschifter, J., et al. (2011). Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am. J. Respir. Cell Mol. Biol. 44, 369-376.
51. Hofmann, S. R., Rösen-Wolff, A., Tsokos, G. C., and Hedrich, C. M. (2012). Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin. Immunol. 143, 116-127.
52. Hofstetter, C., Flondor, M., Hoegl, S., Muhl, H., and Zwissler, B. (2005). Interleukin-10 aerosol reduces proinflammatory mediators in bronchoalveolar fluid of endotoxemic rat. Crit. Care Med. 33, 2317-2322.
53. Huber, C., Batchelor, J. R., Fuchs, D., Hausen, A., Lang, A., Niederwieser, D., et al. (1984). Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160, 310-316.
54. Ikeuchi, H., Kuroiwa, T., Hiramatsu, N., Kaneko, Y., Hiromura, K., Ueki, K., et al. (2005). Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52, 1037-1046.
55. Isler, P., de Rochemonteix, B. G., Songeon, F., Boehringer, N., and Nicod, L. P. (1999). Interleukin-12 production by human alveolar macrophages is controlled by the autocrine production of interleukin-10. Am. J. Respir. Cell Mol. Biol. 20, 270-278.
56. Ito, S., Ansari, P., Sakatsume, M., Dickensheets, H., Vazquez, N., Donnelly, R. P., et al. (1999). Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93, 1456-1463.
57. Ivashkiv, L. B. (2003). Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 36, 473-479.
58. Jacobs, F., Chaussabel, D., Truyens, C., Leclerq, V., Carlier, Y., Goldman, M., et al. (1998). IL-10 up-regulates nitric oxide (NO) synthesis by lipopolysaccharide (LPS)-activated macrophages: improved control of Trypanosoma cruzi infection. Clin. Exp. Immunol. 113, 59-64.
59. Jarnicki, A., Putoczki, T., and Ernst, M. (2010). Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div. 5, 14.
60. John, M., Oltmanns, U., Fietze, I., Witt, C., and Jung, K. (2002). Increased production of matrix metalloproteinase-2 in alveolar macrophages and regulation by interleukin-10 in patients with acute pulmonary sarcoidosis. Exp. Lung Res. 28, 55-68.
61. Kalliolias, G. D., and Ivashkiv, L. B. (2010). Overview of the biology of type I interferons. Arthritis Res. Ther. 12(Suppl. 1), :S1.
62. Karonitsch, T., von Dalwigk, K., Steiner, C. W., Blüml, S., Steiner, G., Kiener, H. P., et al. (2012). Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 64, 400-408.
63. Kaser, A., Novick, D., Rubinstein, M., Siegmund, B., Enrich, B., Koch, R. O., et al. (2002). Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin. Exp. Immunol. 129, 332-338.
64. Katakura, K., Lee, J., Rachmilewitz, D., Li, G., Eckmann, L., and Raz, E. (2005). Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115, 695-702.
65. Kim, K. W., Kim, H. R., Park, J. Y., Park, J. S., Oh, H. J., Woo, Y. J., et al. (2012). Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 64, 1015-1023.
66. Kimball, A. B., Kawamura, T., Tejura, K., Boss, C., Hancox, A. R., Vogel, J. C., et al. (2002). Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch. Dermatol. 138, 1341-1346.
67. Kontoyiannis, D., Kotlyarov, A., Carballo, E., Alexopoulou, L., Blackshear, P. J., Gaestel, M., et al. (2001). Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology. EMBO J. 20, 3760-3770.
68. Krumbholz, M., Faber, H., Steinmeyer, F., Hoffmann, L. A., Kümpfel, T., Pellkofer, H., et al. (2008). Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131, 1455-1463.
69. Kubo, M., and Motomura, Y. (2012). Transcriptional regulation of the anti-inflammatory cytokine IL-10 in acquired immune cells. Front. Immunol. 3:275. doi:10.3389/fimmu.2012.00275
70. Kuga, S., Otsuka, T., Niiro, H., Nunoi, H., Nemoto, Y., Nakano, T., et al. (1996). Suppression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. Exp. Hematol. 24, 151-157.
71. Kulkarni, A. B., Ward, J. M., Yaswen, L., Mackall, C. L., Bauer, S. R., Huh, C. G., et al. (1995). Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 146, 264-275.
72. Kumar, P., Thakar, M. S., Ouyang, W., and Malarkannan, S. (2013). IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol. 6, 69-82.
73. La Mantia, L., and Capsoni, F. (2010). Psoriasis during interferon beta treatment for multiple sclerosis. Neurol. Sci. 31, 337-339.
74. Lauw, F. N., Pajkrt, D., Hack, C. E., Kurimoto, M., van Deventer, S. J., and van der Poll, T. (2000). Proinflammatory effects of IL-10 during human endotoxemia. J. Immunol. 165, 2783-2789.
75. Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., and Tough, D. F. (2001). Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470.
76. Leipe, J., Schramm, M. A., Grunke, M., Baeuerle, M., Dechant, C., Nigg, A. P., et al. (2011). Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann. Rheum. Dis. 70, 1453-1457.
77. Li, H. S., Gelbard, A., Martinez, G. J., Esashi, E., Zhang, H., Nguyen-Jackson, H., et al. (2011). Cell-intrinsic role for IFN-α-STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. Blood 118, 3879-3889.
78. Liu, B. S., Janssen, H. L., and Boonstra, A. (2012). Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. Eur. J. Immunol. 42, 2431-2440.
79. Llorente, L., Richaud-Patin, Y., García-Padilla, C., Claret, E., Jakez-Ocampo, J., Cardiel, M. H., et al. (2000). Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43, 1790-1800.
80. Mantovani, A., Cassatella, M. A., Costantini, C., and Jaillon, S. (2011). Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519-531.
81. Martinelli, S., Urosevic, M., Daryadel, A., Oberholzer, P. A., Baumann, C., Fey, M. F., et al. (2004). Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J. Biol. Chem. 279, 44123-44132.
82. Matikainen, S., Paananen, A., Miettinen, M., Kurimoto, M., Timonen, T., Julkunen, I., et al. (2001). IFN-alpha and IL-18 synergistically enhance IFN-gamma production in human NK cells: differential regulation of Stat4 activation and IFN-gamma gene expression by IFN-alpha and IL-12. Eur. J. Immunol. 31, 2236-2245.
83. McRae, B. L., Semnani, R. T., Hayes, M. P., and van Seventer, G. A. (1998). Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J. Immunol. 160, 4298-4304.
84. Mehrotra, P. T., Donnelly, R. P., Wong, S., Kanegane, H., Geremew, A., Mostowski, H. S., et al. (1998). Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J. Immunol. 160, 2637-2644.
85. Miossec, P., Korn, T., and Kuchroo, V. K. (2009). Interleukin-17 and type 17 helper T cells. N. Engl. J. Med. 361, 888-898.
86. Mitani, Y., Takaoka, A., Kim, S. H., Kato, Y., Yokochi, T., Tanaka, N., et al. (2001). Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6, 631-640.
87. Mühl, H., Bachmann, M., and Pfeilschifter, J. (2011). Inducible NO synthase and antibacterial host defence in times of Th17/Th22/T22 immunity. Cell. Microbiol. 13, 340-348.
88. Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., et al. (2011). IL-10 elicits IFNγ-dependent tumor immune surveillance. Cancer Cell 20, 781-796.
89. Munk, R. B., Sugiyama, K., Ghosh, P., Sasaki, C. Y., Rezanka, L., Banerjee, K., et al. (2011). Antigen-independent IFN-γ production by human naïve CD4 T cells activated by IL-12 plus IL-18. PLoS ONE 6:e18553. doi:10.1371/journal.pone.0018553
90. Nagalakshmi, M. L., Rascle, A., Zurawski, S., Menon, S., and de Waal Malefyt, R. (2004). Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int. Immunopharmacol. 4, 679-691.
91. Nakajima, H., Nakajima, K., Tarutani, M., Morishige, R., and Sano, S. (2011). Kinetics of circulating Th17 cytokines and adipokines in psoriasis patients. Arch. Dermatol. Res. 303, 451-355.
92. Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., et al. (2005). Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202, 135-143.
93. Nograles, K. E., Zaba, L. C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., et al. (2008). Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159, 1092-1102.
94. Nold, M., Goede, A., Eberhardt, W., Pfeilschifter, J., and Mühl, H. (2003). IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNFalpha blockage and modulation by IL-10. Naunyn Schmiedebergs Arch. Pharmacol. 367, 68-75.
95. Nold, M. F., Nold-Petry, C. A., Zepp, J. A., Palmer, B. E., Bufler, P., and Dinarello, C. A. (2010). IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11, 1014-1022.
96. Novick, D., Cohen, B., and Rubinstein, M. (1994). The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77, 391-400.
97. Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A., and Hymowitz, S. G. (2011). Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29, 71-109.
98. Paget, C., Ivanov, S., Fontaine, J., Renneson, J., Blanc, F., Pichavant, M., et al. (2012). Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages. J. Biol. Chem. 287, 8816-8829.
99. Paludan, S. R. (2000). Synergistic action of pro-inflammatory agents: cellular and molecular aspects. J. Leukoc. Biol. 67, 18-25.
100. Pan, H., Hong, F., Radaeva, S., and Gao, B. (2004). Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell. Mol. Immunol. 1, 43-49.
101. Parato, K. G., Kumar, A., Badley, A. D., Sanchez-Dardon, J. L., Chambers, K. A., Young, C. D., et al. (2002). Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. AIDS 16, 1251-1256.
102. Park, J. Y., Lee, S. H., Yoon, S. R., Park, Y. J., Jung, H., Kim, T. D., et al. (2001). IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells. Mol. Cells 32, 265-272.
103. Park, O., Wang, H., Weng, H., Feigenbaum, L., Li, H., Yin, S., et al. (2011). In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology 54, 252-261.
104. Paul, G., Khare, V., and Gasche, C. (2012). Inflamed gut mucosa: downstream of interleukin-10. Eur. J. Clin. Invest. 42, 95-109.
105. Pickert, G., Neufert, C., Leppkes, M., Zheng, Y., Wittkopf, N., Warntjen, M., et al. (2009). STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465-1472.
106. Platanias, L. C. (2005). Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375-386.
107. Prinz, M., and Kalinke, U. (2010). New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS. Trends Mol. Med. 16, 379-386.
108. Qian, C., Jiang, X., An, H., Yu, Y., Guo, Z., Liu, S., et al. (2006). TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 108, 2307-2315.
109. Radaeva, S., Sun, R., Pan, H. N., Hong, F., and Gao, B. (2004). Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39, 1332-1342.
110. Ramgolam, V. S., Sha, Y., Jin, J., Zhang, X., and Markovic-Plese, S. (2009). IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 183, 5418-5427.
111. Reznikov, L. L., Puren, A. J., Fantuzzi, G., Mühl, H., Shapiro, L., Yoon, D. Y., et al. (1998). Spontaneous and inducible cytokine responses in healthy humans receiving a single dose of IFN-alpha2b: increased production of interleukin-1 receptor antagonist and suppression of IL-1-induced IL-8. J. Interferon Cytokine Res. 18, 897-903.
112. Sabat, R., and Wolk, K. (2011). Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis. J. Dtsch. Dermatol. Ges. 9, 518-523.
113. Santin, A. D., Hermonat, P. L., Ravaggi, A., Bellone, S., Pecorelli, S., Roman, J. J., et al. (2000). Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J. Virol. 74, 4729-4737.
114. Sareneva, T., Julkunen, I., and Matikainen, S. (2000). IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J. Immunol. 165, 1933-1938.
115. Satoh-Takayama, N., Vosshenrich, C. A., Lesjean-Pottier, S., Sawa, S., Lochner, M., Rattis, F., et al. (2008). Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29, 958-970.
116. Savan, R., McFarland, A. P., Reynolds, D. A., Feigenbaum, L., Ramakrishnan, K., Karwan, M., et al. (2011). A novel role for IL-22R1 as a driver of inflammation. Blood 117, 575-584.
117. Scheiermann, P., Bachmann, M., Goren, I., Zwissler, B., Pfeilschifter, J., and Mühl, H. (2012). Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am. J. Pathol. (in press).
118. Schott, E., Paul, F., Wuerfel, J. T., Zipp, F., Rudolph, B., Wiedenmann, B., et al. (2007). Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J. Gastroenterol. 13, 3638-3640.
119. Schreiber, S., Rosenstiel, P., Hampe, J., Nikolaus, S., Groessner, B., Schottelius, A., et al. (2002). Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 51, 379-385.
120. Severa, M., Remoli, M. E., Giacomini, E., Annibali, V., Gafa, V., Lande, R., et al. (2007). Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. J. Immunol. 178, 6208-6216.
121. Sharif, M. N., Tassiulas, I., Hu, Y., Mecklenbräuker, I., Tarakhovsky, A., and Ivashkiv, L. B. (2004). IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J. Immunol. 172, 6476-6481.
122. Shibata, Y., Foster, L. A., Kurimoto, M., Okamura, H., Nakamura, R. M., Kawajiri, K., et al. (1998). Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J. Immunol. 161, 4283-4288.
123. Sonnenberg, G. F., Fouser, L. A., and Artis, D. (2011). Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12, 383-390.
124. Sonnenberg, G. F., Monticelli, L. A., Alenghat, T., Fung, T. C., Hutnick, N. A., Kunisawa, J., et al. (2012). Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336, 1321-1325.
125. Souza-Fonseca-Guimaraes, F., Adib-Conquy, M., and Cavaillon, J. M. (2012). Natural killer (NK) cells in antibacterial innate immunity: angels or devils? Mol. Med. 18, 270-285.
126. Sprenger, R., Sagmeister, M., and Offner, F. (2005). Acute ulcerative colitis during successful interferon/ribavirin treatment for chronic hepatitis. Gut 54, 438-439.
127. Sugimoto, K., Ogawa, A., Mizoguchi, E., Shimomura, Y., Andoh, A., Bhan, A. K., et al. (2008). IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118, 534-544.
128. Swann, J. B., Hayakawa, Y., Zerafa, N., Sheehan, K. C., Scott, B., Schreiber, R. D., et al. (2007). Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178, 7540-7549.
129. Takaoka, A., Mitani, Y., Suemori, H., Sato, M., Yokochi, T., Noguchi, S., et al. (2000). Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 288, 2357-2360.
130. Takaoka, A., and Yanai, H. (2006). Interferon signalling network in innate defence. Cell. Microbiol. 8, 907-922.
131. Taniguchi, T., and Takaoka, A. (2001). A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2, 378-386.
132. Teige, I., Treschow, A., Teige, A., Mattsson, R., Navikas, V., Leanderson, T., et al. (2003). IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. J. Immunol. 170, 4776-4784.
133. Tilg, H., van Montfrans, C., van den Ende, A., Kaser, A., van Deventer, S. J., Schreiber, S., et al. (2002). Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50, 191-195.
134. Tohyama, M., Yang, L., Hanakawa, Y., Dai, X., Shirakata, Y., and Sayama, K. (2012). IFN-α enhances IL-22 receptor expression in keratinocytes: a possible role in the development of psoriasis. J. Invest. Dermatol. 132, 1933-1935.
135. Treschow, A. P., Teige, I., Nandakumar, K. S., Holmdahl, R., and Issazadeh-Navikas, S. (2005). Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum. 52, 3739-3748.
136. Trinchieri, G. (2010). Type I interferon: friend or foe? J. Exp. Med. 207, 2053-2063.
137. van Baarsen, L. G., Vosslamber, S., Tijssen, M., Baggen, J. M., van der Voort, L. F., Killestein, J., et al. (2008). Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 3:e1927. doi:10.1371/journal.pone.0001927
138. Van Belle, A. B., de Heusch, M., Lemaire, M. M., Hendrickx, E., Warnier, G., Dunussi-Joannopoulos, K., et al. (2012). IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J. Immunol. 188, 462-469.
139. van den Broek, M. F., Müller, U., Huang, S., Zinkernagel, R. M., and Aguet, M. (1995). Immune defence in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148, 5-18.
140. van Holten, J., Smeets, T. J., Blankert, P., and Tak, P. P. (2005). Expression of interferon beta in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann. Rheum. Dis. 64, 1780-1782.
141. Walmsley, M., Katsikis, P. D., Abney, E., Parry, S., Williams, R. O., Maini, R. N., et al. (1996). Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum. 39, 495-503.
142. Wang, H., Lafdil, F., Kong, X., and Gao, B. (2011). Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int. J. Biol. Sci. 7, 536-550.
143. Wang, K., Scheel-Toellner, D., Wong, S. H., Craddock, R., Caamano, J., Akbar, A. N., et al. (2003). Inhibition of neutrophil apoptosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways. J. Immunol. 171, 1035-1041.
144. Wang, P., Bai, F., Zenewicz, L. A., Dai, J., Gate, D., Cheng, G., et al. (2012). IL-22 signaling contributes to west nile encephalitis pathogenesis. PLoS ONE 7:e44153. doi:10.1371/journal.pone.0044153
145. Watanabe, T., Inoue, M., Harada, K., Homma, N., Uchida, M., Ogata, N., et al. (2006). A case of exacerbation of ulcerative colitis induced by combination therapy with PEG-interferon alpha-2b and ribavirin. Gut 55, 1682-1683.
146. Webster, G. F., Knobler, R. L., Lublin, F. D., Kramer, E. M., and Hochman, L. R. (1996). Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J. Am. Acad. Dermatol. 34, 365-367.
147. Witkowska, A. M. (2005). On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm. 2005, 121-130.
148. Wittmann, M., Doble, R., Bachmann, M., Pfeilschifter, J., Werfel, T., and Mühl, H. (2012). IL-27 regulates IL-18 binding protein in skin resident cells. PLoS ONE 7:e38751. doi:10.1371/journal.pone.0038751
149. Wolk, K., Haugen, H. S., Xu, W., Witte, E., Waggie, K., Anderson, M., et al. (2009). IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J. Mol. Med. (Berl.) 87, 523-536.
150. Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K., and Sabat, R. (2004). IL-22 increases the innate immunity of tissues. Immunity 21, 241-254.
151. Wolk, K., Witte, E., Witte, K., Warszawska, K., and Sabat, R. (2010). Biology of interleukin-22. Semin. Immunopathol. 32, 17-31.
152. Xie, M. H., Aggarwal, S., Ho, W. H., Foster, J., Zhang, Z., Stinson, J., et al. (2000). Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J. Biol. Chem. 275, 31335-31339.
153. Xing, W. W., Zou, M. J., Liu, S., Xu, T., Wang, J. X., and Xu, D. G. (2011). Interleukin-22 protects against acute alcohol-induced hepatotoxicity in mice. Biosci. Biotechnol. Biochem. 75, 1290-1294.
154. Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809.
155. Zenewicz, L. A., Yancopoulos, G. D., Valenzuela, D. M., Murphy, A. J., Karow, M., and Flavell, R. A. (2007). Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 27, 647-659.
156. Zenewicz, L. A., Yancopoulos, G. D., Valenzuela, D. M., Murphy, A. J., Stevens, S., and Flavell, R. A. (2008). Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29, 947-957.
157. Zhang, S. Y., Boisson-Dupuis, S., Chapgier, A., Yang, K., Bustamante, J., Puel, A., et al. (2008a). Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol. Rev. 226, 29-40.
158. Zhang, W., Chen, Y., Wei, H., Zheng, C., Sun, R., Zhang, J., et al. (2008b). Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin. Cancer Res. 14, 6432-6439.
159. Zhang, Y., Cobleigh, M. A., Lian, J. Q., Huang, C. X., Booth, C. J., Bai, X. F., et al. (2011). A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 141, 1897-1906.
160. Zheng, Y., Valdez, P. A., Danilenko, D. M., Hu, Y., Sa, S. M., Gong, Q., et al. (2008). Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14, 282-289.
161. Zhu, J., Huang, X., and Yang, Y. (2008). A critical role for type I IFN-dependent NK cell activation in innate immune elimination of adenoviral vectors in vivo. Mol. Ther. 16, 1300-1307.
162. Ziesché, E., Bachmann, M., Kleinert, H., Pfeilschifter, J., and Mühl, H. (2007). The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J. Biol. Chem. 282, 16006-16015.